[1] Mrowietz U, et al. Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study. Dermatol Ther (Heidelb). 2021 Apr;11(2):571-585. DOI:
10.1007/s13555-021-00504-0[2] Geller S, et al. CCR4 expression in CD8+ cutaneous T-cell lymphomas and lymphoproliferative disorders and its implications for diagnosis and treatment[C]//Journal of Investigative Dermatology. STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA: ELSEVIER SCIENCE INC, 2019, 139(9): B25-B25.
[3] Jennifer Ahlberg, et al. Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5). MAbs. 2019 Jul;11(5):956-964. DOI:
10.1080/19420862.2019.1615345[4] Rajkumar Ganesan, et al. Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies.MAbs. 2017 Oct;9(7):1143-1154. DOI:
10.1080/19420862.2017.1353853 